A CA‑125 level above about 35 U/mL is generally considered elevated and may raise suspicion for ovarian cancer. Small increases occur with many benign conditions (e.g., menstruation, endometriosis, liver disease), while very high values—often several hundred U/mL—are more suggestive of malignancy. CA‑125 is not diagnostic alone; interpretation requires symptoms, imaging, menopausal status, and sometimes biopsy.

CA‑125 (cancer antigen 125) is a protein measured in blood and used as a tumor marker. Levels often rise in ovarian cancer and help monitor treatment response or detect recurrence, but the test isn’t specific: benign conditions (menstruation, endometriosis, pregnancy, pelvic infection, liver disease, heart failure) can also raise it. Typical cutoff is about 35 U/mL; clinical context is essential.

CA‑125 is a blood protein used as a tumor marker, especially for ovarian disease. During pregnancy it often rises—most commonly in the first trimester and near delivery—due to placental, decidual and pelvic changes, so elevations are frequently benign. Because pregnancy alters levels, CA‑125 is unreliable for cancer screening in pregnancy; abnormal results need careful clinical assessment and imaging.

CA‑125 is a blood protein that can be raised in ovarian cancer, but it is neither sensitive nor specific enough to reliably detect early cancer. Levels may be normal in early disease and can rise with many benign conditions. CA‑125 is useful for monitoring treatment or recurrence and, when combined with imaging and risk models, may aid evaluation—but it is not recommended alone as a screening test.

Stress by itself is not known to directly raise CA‑125. CA‑125 increases with ovarian cancer and many benign conditions (e.g., menstruation, endometriosis, fibroids, inflammation, liver disease, recent surgery). Severe or chronic stress can worsen inflammation or health conditions that might indirectly influence CA‑125, but stress alone isn’t a proven cause. Discuss abnormal results with your clinician for repeat testing and imaging.

No single blood test definitively shows cancer. Blood tests can detect tumor markers (PSA, CEA, CA‑125, CA19‑9), abnormal complete blood count results, elevated lactate dehydrogenase or liver enzymes, and circulating tumor DNA—findings that may suggest cancer. Tumor markers and blood abnormalities support screening or monitoring but are not diagnostic; imaging and tissue biopsy are required for confirmation.